The lncRNA, MEG3, which regulates the insulin signaling pathway implicated in the molecular mechanism of T3D, may be a molecular therapeutic target for managing the onset of complications and the advancement of the disease brought on by diabetes and Alzheimer’s disease. This evidence concerns the gene INS and Alzheimer disease.